Merck & Co., Inc. Number of Reportable Segments
Merck & Co., Inc. (MRK) reported Number of Reportable Segments of 2 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-07
- Merck & Co., Inc. number of reportable segments for fiscal 2013 was 1.00 Segment.
Segment
| Period end | Number of Reportable Segments 12 month |
|---|---|
| 2013-12-31 | 1.00 Segment 10-K · filed 2014-02-27 |
segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2026-06-30 | 2.00 segment 10-Q · filed 2026-08-07 | ||
| 2026-03-31 | 2.00 segment 10-Q · filed 2026-05-04 | ||
| 2025-12-31 | 2.00 segment 10-K · filed 2026-02-24 | ||
| 2014-12-31 | 1.00 segment 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |